Update on BCR-ABL1-like precursor B-cell acute lymphoblastic leukemia

Abstract

Precursor B-cell acute lymphoblastic leukemia (B-ALL) is the most common type of leukemia in children and young adults. Our understanding of the genetic basis of B-ALL has greatly improved in recent years. Application of genomic profiling and sequencing has led to the identification of a clinically important subgroup of B-ALL patients who are BCR-ABL1 negative, but exhibit a gene expression profile similar to that of BCR-ABL1-positive ALL. This new subgroup has been referred to as BCR-ABL1-like ALL. Like BCR-ABL1-positive ALL, BCR-ABL1-like ALL patients are in the high-risk category, associated with poor outcome. The BCR-ABL1-like patients have a diverse range of genetic alterations that activate tyrosine kinase signaling. The recurrent genetic changes include ABL class- or JAK pathway-associated translocations and IKZF1 deletions. Herein, we review the recent progress in BCR-ABL1-like ALL, the recurrent genetic alterations seen in these patients, and the therapeutic potential of targeting the identified molecular changes.

Keywords

ALL, BCR-ABL1-like, Ph-like, ABL-rearrangements, JAK2-rearrangements, IKZF1

How to Cite

Lokhandwala, P. M. & Ning, Y., (2016) “Update on BCR-ABL1-like precursor B-cell acute lymphoblastic leukemia”, Hematopathology 1(1), p.11-15.

90

Views

11

Downloads

Share

Authors

Parvez M. Lokhandwala (Johns Hopkins University School of Medicine)
Yi Ning (Johns Hopkins University School of Medicine)

Download

Issue

Publication details

Dates

Licence

Creative Commons Attribution-NonCommercial 4.0

Peer Review

This article has been peer reviewed.

File Checksums (MD5)

  • PDF: 84b807293d0f17da55e86c63129cd061